Advice
NICE is unable, at this time, to make a recommendation about the use in the NHS of toripalimab with chemotherapy for untreated advanced oesophageal squamous cell cancer in adults. This is because Shanghai Junshi Bioscience has requested a delay to the evidence submission.
Information
If NHS organisations wish to consider toripalimab for this indication, they should follow the advice on rational local decision making in the NHS Constitution for England and the NHS Commissioning Board and Clinical Commissioning Groups (Responsibilities and Standing Rules) Regulations 2012. This outlines the approach that should be taken when there is no NICE guidance.
NICE will review the position when the company makes an evidence submission.
ISBN: 978-1-4731-6669-1